Clinical and Hematological Features of 335 Patients of Chronic Myelogenous Leukemia Diagnosed at Single Centre in Northern Pakistan
Authors:
Open Access
- 1 January 2012
- journal article
- Published by SAGE Publications in Clinical medicine. Blood disorders
- Vol. 5
Abstract
There are no studies regarding analysis of clinical and haematological features of chronic myelogenous leukemia (CML) from Pakistan. This study analyzes the data of patients suffering from CML, reporting to a major referral Institute in Northern Pakistan in the past 6 years and 3 months. CML constitutes approximately 80% of all myeloproliferative disorders, with a peak incidence between 21-50 years of age, and a male:female ratio of 2:1. Anaemia and massive splenomegaly were the main clinical features found in 92% and 47% patients respectively. There was significant correlation between anaemia and WBC counts with degree of splenomegaly. Three percent of all CML patients presented as de novo accelerated phase, and another 3% presented as blast crises without any previous history of chronic phase. The ratio of myeloid and lymphoid blast crisis was 2:1. Median duration of chronic phase in patients on hydroxyurea treatment was 6 years. Thirty six percent of patients in chronic phase of CML belonged to intermediate and high risk according to Sokal and Hasford scoring systems. In contrast to the Caucasian populations where the peak incidence of the disease is in 6th to 7th decade, CML occurs in Pakistan in a much younger population, with a broad peak between 21-50 years of age. Patients present in fairly advanced disease because of poor access to health care facilities, due to non-affordability and lack of health insurance coverage.Keywords
This publication has 22 references indexed in Scilit:
- The incidence of and mortality from leukaemias in the UK: a general population-based studyBMC Cancer, 2009
- Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAPGlobalization and Health, 2009
- The spectrum of adult B‐lymphoid leukemias with BCR‐ABL: Molecular diagnostic, cytogenetic, and clinical laboratory perspectivesAmerican Journal of Hematology, 2008
- Treatment of chronic myeloid leukemia in the imatinib eraCancer, 2007
- The age incidence of chronic myeloid leukemia can be explained by a one-mutation modelProceedings of the National Academy of Sciences, 2006
- The biology of CML blast crisisBlood, 2004
- Chronic myelogenous leukemia: A review and update of therapeutic strategiesCancer, 2003
- CHRONIC MYELOGENOUS LEUKAEMIABritish Journal of Haematology, 2000
- Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year periodBritish Journal of Haematology, 1997
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990